Join to View Full Profile
593 Eddy StProvidence, RI 02903
Phone+1 401-444-8450
Fax+1 401-444-5088
Dr. Perez is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2010
George Washington University School of Medicine and Health SciencesClass of 2004
Certifications & Licensure
MA State Medical License 2015 - 2028
RI State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Start of enrollment: 2014 Aug 01
- Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
- Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer Start of enrollment: 2018 Dec 05
Publications & Presentations
PubMed
- Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.Kimberly J Perez, Andressa Dias Costa, Alexander Jordan, Thomas B Karasic, Dalia Elganainy
Nature Cancer. 2026-05-25 - Dendritic cell redundancy enables priming of anti-tumor CD4T cells in pancreatic cancer.Courtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, Victoire Cardot-Ruffino, Dennis A Agardy
Cancer Cell. 2026-05-07 - A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, Nora Horick, Yvonne Y Li
Clinical Cancer Research. 2026-05-01
Journal Articles
- Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic CancerRichard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature
Lectures
- Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Dana-Farber Cancer Institute, Brigham and Women''s Hospital Designated as Rare Disease Clinical CenterJune 29th, 2022- Dana-Farber Cancer Institute/Brigham and Women’s Hospital Designated as Rare Disease Clinical Center for Pheochromocytoma &June 28th, 2022
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerJanuary 27th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
